CLOs on the Move

CipherHealth

www.cipherhealth.com

 
CipherHealth is an award-winning and proven technology solutions partner committed to enhancing communication and care throughout the patient journey. Since 2009, CipherHealth has helped shape the patient engagement category, delivering groundbreaking products to help care providers effectively and efficiently deliver quality care for their patients. CipherHealth`s suite of patient engagement programs sets new standards for care and empowers healthcare organizations to create purposeful conversations to ensure the best possible outcomes for staff members, patients, and their loved ones.
  • Number of Employees: 100-250
  • Annual Revenue: $10-50 Million

Executives

Name Title Contact Details

Similar Companies

Field Crest Care Ctr

Field Crest Care Ctr is a Hayfield, MN-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Somnia Inc

Somnia Inc is one of the leading providers in Healthcare, Pharmaceuticals, & Biotech. It is based in New Rochelle, NY. To find more information about Somnia Inc, please visit www.somniainc.com

Marina Care Ctr

Marina Care Ctr is a Culver City, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

ForSight Labs, LLC

ForSight Labs, LLC is one of the leading providers in Healthcare, Pharmaceuticals, & Biotech. It is based in Menlo Park, CA. To find more information about ForSight Labs, LLC, please visit www.forsightlabs.com

ContraVir Pharmaceuticals, Inc

ContraVir is a biopharmaceutical company focused primarily on the development of drugs to treat herpes zoster, or shingles, which is an infection caused by the reactivation of varicella zoster virus or VZV. Our lead candidate, FV-100, is an orally available nucleoside analogue prodrug of CF-1743 that we are developing for the treatment of shingles. Published preclinical studies demonstrate that FV-100 is significantly more potent against VZV than acyclovir, valacyclovir, and famciclovir, the FDA-approved drugs used for the treatment of shingles. Preclinical studies further demonstrate that FV-100 has a more rapid onset of antiviral activity, and may fully inhibit the replication of VZV more rapidly than these drugs at significantly lower concentration levels. In addition, pharmacokinetic data from completed phase 1 and 2 clinical trials suggest that FV-100 has the potential to demonstrate antiviral activity when dosed orally once-a-day at significantly lower levels than valacyclovir, acyclovir, and famciclovir.